On the other hand, recent studies have suggested that inhibition of sodium-glucose cotransporters (SGLTs), such as SGLT2 inhibitors, which lower blood glucose levels through the promotion of urinary glucose excretion without increasing insulin levels, may offer a beneficial effect on NASH through inhibition of hepatic lipid accumulation. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatohepatitis.